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News & Views
CSF sTREM2: marking the tipping point
between preclinical AD and dementia?
Suzanne E Schindler1,2,3 & David M Holtzman1,2,3
Biomarkers for Alzheimer’s disease (AD)
have improved our understanding of the
temporal sequence of biological events
that lead to AD dementia (Jack et al,
2013). AD is characterized neuropathologi-
cally by amyloid plaques comprised of the
amyloid-b peptide and neurofibrillary
tangles comprised of tau. Brain amyloid
deposition, as evidenced by a decline in
amyloid-b peptide 42 (Ab42) in the cere-
brospinal fluid (CSF) or by binding of
amyloid PET ligands, is thought to be a key
initiating event in AD and begins many
years prior to the onset of dementia. A rise
in CSF tau and phosphorylated tau in the
setting of Ab deposition appears to reflect
neurodegeneration and also begins years
prior to the onset of dementia but after
Ab deposition has begun to accumulate.
Individuals with “preclinical AD,” that is,
normal cognition but abnormal AD
biomarkers, have a much higher risk for
developing AD dementia but may remain
cognitively normal for years (Vos et al,
2013). While deposition of amyloid and
formation of tau tangles are necessary for
AD to occur, it is likely that additional
events involving inflammation or other
processes contribute to crossing the
tipping point from preclinical AD to AD
dementia. Current efforts are aimed at
defining the biomarker(s) that best predict
the transition from cognitive normality to
abnormality. A biomarker that is closely
associated with the onset of cognitive
decline could help us to understand the
biological events that connect amyloid
deposition and tangle formation to cogni-
tive decline and could have significant
practical value in AD diagnosis and clinical
trial design.
See also: M Suárez-Calvet et al (May 2016)
A D researchers have long suspectedthat inflammation plays an impor-tant role in the biology of AD, but
genetic evidence was largely lacking until
2013, when two studies reported that rare,
missense mutations in TREM2 (triggering
receptor expressed on myeloid cells 2)
increased risk for AD by about twofold to
fourfold (Guerreiro et al, 2013; Jonsson
et al, 2013). Since then the biology of
TREM2, and the role of TREM2 in AD, has
been a very active area of investigation (for
review see Ulrich & Holtzman, 2016).
TREM2 is a receptor that is expressed on
phagocytic cells, including microglia, and
can activate a number of different signaling
cascades that modulate inflammatory
cytokines and other processes. Mice that
express mutant human APP and develop
amyloid deposition have upregulation in
TREM2 in regions with amyloid deposition
(Frank et al, 2008). One report suggested
that loss-of-function mutations in TREM2
decrease the phagocytic activity of micro-
glia and reduce Ab clearance (Kleinberger
et al, 2014). Further, mice with brain
amyloid deposition and TREM2 haploinsuf-
ficiency have decreased clustering of micro-
glia around amyloid plaques (Ulrich et al,
2014). Although the details of how TREM2
modulates risk for AD remain to be clari-
fied, it appears that TREM2 helps to medi-
ate a protective inflammatory response to
amyloid pathology. Thus, TREM2 may be a
link between amyloid pathology and
complex downstream events including
inflammation.
In their paper, Sua´rez-Calvet et al (2016)
examined CSF levels of the soluble ectodo-
main of TREM2 (sTREM2) in individuals
representing the spectrum of AD, from
cognitively normal with no biomarker
evidence of AD pathology to preclinical AD
to mild cognitive impairment (MCI) to AD
dementia. Interestingly, they found that
levels of CSF sTREM2 were lowest in
controls and preclinical AD, peaked in MCI-
AD, and then declined slightly in AD demen-
tia. The authors also found correlations
between CSF sTREM2 and CSF Ab42, tau,
and ptau. CSF sTREM2 levels correlated
better with CSF tau and ptau levels than
Ab42 levels, suggesting that elevated
sTREM2 levels occur later in the course of
the AD process. Two other groups also
recently reported that CSF sTREM2 levels
are elevated in AD cases compared to cogni-
tively normal controls and that sTREM2
levels are correlated with CSF tau and ptau
(Heslegrave et al, 2016; Piccio et al, 2016).
However, these groups did not examine how
sTREM2 levels changed across the AD spec-
trum. Although the findings of Sua´rez-Calvet
et al (2016) are cross-sectional in nature and
must be replicated in cohorts sampled and
followed longitudinally, they show that CSF
sTREM2 levels may increase at the onset of
cognitive decline (see Fig 1).
If CSF sTREM2 levels are reproducibly
associated with the onset of cognitive
decline, this biomarker could have signifi-
cant value in AD diagnostics and drug
trials. Current clinical CSF diagnostics
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evaluate levels of Ab42, tau, and ptau. The
combination of low CSF Ab42 and high
tau/ptau is consistent with the presence of
AD pathology, but it is not specific—it may
occur either in patients with dementia due
to AD or preclinical AD. Addition of
sTREM2 to CSF testing may improve our
ability to determine whether mild cognitive
problems are due to AD or other etiologies.
CSF sTREM2 levels could also be helpful in
AD drug trials. Biomarkers are being used
as endpoints as well as enrollment criteria
in some clinical trials. If CSF sTREM2 is
reliably associated with the onset of cogni-
tive decline, reduced sTREM2 levels in
drug-treated individuals with preclinical AD
could indicate a favorable drug effect. Addi-
tionally, drugs for AD may be most effec-
tive when given at a particular stage of the
AD process. Individuals who have abnor-
mal biomarkers for amyloid, tau/ptau but
normal CSF sTREM2 may be at an earlier
stage of the AD process than individuals
with abnormalities in all three biomarkers.
If CSF sTREM2 further refines our ability to
stage AD, this would allow us to evaluate
which drugs are most appropriate for
patients at various stages of the AD process.
If additional studies confirm the results of
Sua´rez-Calvet et al (2016), CSF sTREM2
levels may be an important biomarker that
represents some of the biological events
that connect amyloid deposition and
neurofibrillary tangle formation to cognitive
decline. A biomarker that marks the transi-
tion from preclinical AD to dementia could
have a major impact on our ability to
understand, diagnose, and treat this formid-
able disease.
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Figure 1. Possible temporal ordering of biomarkers along the AD time course incorporating CSF
sTREM2.
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